Info

🌱 來自: Enfortumab vedotin

kfsyscc-of-Enfortumab vedotin

• Padcev powder for infusion 30 mg/24kg enfortumab vedotin/vial 備思復凍晶注射劑 IENFO3 (臨採)
• 常用劑量
  • Urothelial cancer, locally advanced or metastatic, combination therapy:
  • IV: 1.25 mg/kg (maximum dose: 125 mg) on days 1 and 8 every 21 days (in combination with pembrolizumab) until disease progression or unacceptable toxicity
  • Urothelial cancer, locally advanced or metastatic, single-agent treatment:
  • IV: 1.25 mg/kg (maximum dose: 125 mg) on days 1, 8, and 15 every 28 days until disease progression or unacceptable toxicity
• 劑量調整
  • Dosage in renal impairment: No dosage adjustment necessary.
  • Dosage in hepatic impairment: Moderate to severe impairment (total bilirubin >1.5 times ULN and any AST): Avoid enfortumab vedotin use.
• 自費價格 30055/24kg = 90000/72kg